Organization of lipid centers operation in the Russian Federation — new opportunities

Project of the Russian National Atherosclerosis Society

In 2016, Guidelines on the medical care organization to the patients with hereditary atherogenic lipid disorders in the regions of Russia were published, which described and presented the principles of routing patients with hereditary dyslipidemia and the organization of medical care for them within the current regulatory documents. In December 2018, the Russian Ministry of Health approved clinical guidelines for the diagnosis and treatment of familial hypercholesterolemia. Thus, persons with a severe hereditary dyslipidemia were able to get free medication with expensive lipid-lowering drugs and receive apheresis. Following the European ones, the Russian guidelines on the management of lipid metabolism disorders were updated: lower target low density lipoprotein cholesterol levels were adopted. In the Russian population, there is a high prevalence of hypercholesterolemia, including familial monogenic and polygenic types. Therefore, timely detection and routing to a lipid center or an office to a specialist (cardiologist, lipidologist), adequate and modern prescription of lipid-lowering therapy will make an important contribution not only to secondary, but also to primary prevention of atherosclerotic cardiovascular complications.

1. Sokolov AA, Alexandrova OYu, Kashtalap VV, et al. Methodical recommendations on the organization of medical care for patients with hereditary atherogenic disorders of lipid metabolism in the subjects of the Russian Federation. The Journal of Atherosclerosis and Dyslipidemias. 2016;4:14-20. (In Russ.)

2. Ezhov MV, Bazhan SS, Ershova AI, et al. Clinical guidelines for familial hypercholesterolemia. The Journal of Atherosclerosis and Dyslipidemias. 2019;1(34):5-43. (In Russ.)

3. Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dysli pidaemias: li pid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.

4. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VII revision. Atherosclerosis and Dyslipidemias. 2020;1(38):7-42. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002

5. Meshkov AN, Ershova AI, Shalnova SA, et al. Cross-sectional Study to Estimate the Prevalence of Familial Hypercholesterolemia in Selected Regions of the Russian Federation: Relevance, Design of the Study and Initial Characteristics of the Participants. Rational Pharmacotherapy in Cardiology. 2020;16(1):24-32. (In Russ.) doi:10.20996/1819-6446-2020-02-17.

6. Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation results of the ESSE-RF study for the years 2012-2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7. (In Russ.) doi:10.15829/1728-8800-2017-4-62-67.

7. Ershova AI, Meshkov AN, Bazhan SS, et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoSOne. 2017;12(7):e0181148. doi:10.1371/journal.pone.0181148.

8. Order of the Ministry of Health of the Russian Federation № 869n of October 26, 2017 “On Approval of the Procedure for Conducting Medical examinations of certain groups of the Adult Population”. (In Russ.)

9. Order of the Ministry of Health of the Russian Federation of 29.03.2019 N 173n “On approval of the procedure for conducting dispensary monitoring of adults” (Registered with the Ministry of Justice of the Russian Federation on 25.04.2019 N 54513). (In Russ.)

10. EAS Familial Hypercholesterolaemia Studies Collaboration; Vallejo-Vaz Antonio J, de Marco Martina, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries — The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234-55. doi:10.1016/j.atherosclerosis.2018.08.051.

11. Ehrlich AD, Barbarash OL, Kashtalap VV, Graziansky NA, on behalf of all participants of the RECORD-3 registery. Compliance with clinical practice guidelines in non ST-segment elevation acute coronary syndrome: association between outcomes and predictors of “poor” management (RECORD-3 registery data). Complex problems of cardiovascular diseases. 2016;5(2):75-82. (In Russ.)

12. Ehrlich AD, Graziansky NA, Participants of the RECORD Registry. The RECORD Registry. Treatment of Patients With Acute Coronary Syndromes in Hospitals With and Without Possibilities to Perform Invasive Coronary Procedures. Kardiologiia. 2010;7:8-14. (In Russ.)

13. Ehrlich AD, Kharchenko MS, Barbarash OL, et al. Adherence to Guidelines on Management of Acute Coronary Syndrome in Russian Hospitals and Outcomes of Hospitalization (Data From the RECORD-2 Registry). Kardiologiia. 2013;1:14-22. (In Russ.)

14. Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8. (In Russ.) doi:10.15829/1728-8800-2012-4-70-78.

15. Sturm AC, Knowles JW, Gidding SS, et al.; Convened by the Familial Hypercholesterolemia Foundation. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018;72(6):662-80. doi:10.1016/j.jacc.2018.05.044.

16. Page MM, Bell DA, Watts GF. Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes? Clin Genet. 2020;97(4):543-55. doi:10.1111/cge.13685.

17. Chubykina UV, Ezhov MV, Ershova AI, et al. Cardiovascular events and effectiveness of hypolipidemic therapy in patients with familial hypercholesterolemia and patients of very high cardiovascular risk: 3-year follow-up of the RENAISSANCE Registry. Kardiologicheskij Vestnik. 2020;3:27-36. (In Russ.) doi:10.36396/MS.2020.16.3.004

18. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.

19. Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021;26(4):4449. (In Russ.) doi:10.15829/1560-4071-2021-4449.

20. Russian Society of Cardiology. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/29/1560-4071-2020-4103.

21. Zhuravleva MV, Prokofiev AB, Shikh EV, et al. PCSK9 Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues. Rational Pharmacotherapy in Cardiology. 2020;16(4):644-53. (In Russ.) doi:10.20996/1819-6446-2020-08-21.

22. Kusters DM, de Beaufort C, Widhalm K, et al. Paediatric screening for hypercholestero-laemia in Europe. Arch Dis Child. 2012;97:272-6. doi:10.1136/archdischild-2011-300081.

23. Ramaswamia U, Humphriesb SE, Priestley-Barnhamc L, et al. Current management of children and young people with heterozygous familial hypercholesterolaemia — HEART UK statement of care. Atherosclerosis. 2019;290:1-8. doi:10.1016/j.atherosclerosis.2019.09.005.

24. La Bresh KA, Lazorick S, Ariza AJ, et al. Implementation of the NHLBI Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Rationale and Study Design for Young Hearts, Strong Starts, a Cluster Randomized Trial Targeting Body Mass Index, Blood Pressure, and Tobacco. Contemp Clin Trials. 2014;37(1):98-105. doi:10.1016/j.cct.2013.11.011.

25. Wiegman A, Gidding S, Watts G, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing. Eur Heart J. 2015;36:2425-37. doi:10.1093/eurheartj/ehv157.

26. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hyper-cholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36(9):560-5. doi:10.1093/eurheartj/ehu058.